

Tolvaptan

Catalog No: tcsc0572



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

150683-30-0

Formula:

$C_{26}H_{25}ClN_2O_3$

Pathway:

GPCR/G Protein;Autophagy

Target:

Vasopressin Receptor;Autophagy

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 100 mg/mL (222.75 mM)

Alternative Names:

OPC-41061

Observed Molecular Weight:

448.94


Product Description

Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28 μ M for the inhibition of AVP-induced platelet aggregation.

IC50 value: 1.28 μ M (inhibition of AVP-induced platelet aggregation)

Target: vasopressin receptor 2

Tolvaptan (OPC-41061) is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28 μ M for the inhibition of AVP-induced platelet aggregation. Tolvaptan (OPC-41061) is used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan (OPC-41061) is also in fast-track clinical trials for polycystic kidney disease. Treatment with t tolvaptan (OPC-41061) causes rapid and sustained body weight reductions concurrent with increases in urine output, improves and/or normalizes serum sodium in hyponatremic patients, reduces signs and symptoms of congestion and increases thirst. However, tolvaptan (OPC-41061) has not been shown to decrease heart failure re-hospitalization or mortality. As an adjunct to standard therapy, tolvaptan (OPC-41061) is unique in that it is virtually the only novel agent tested in patients hospitalized for acute heart failure syndrome (AHFS) to reach its primary end point for short-term efficacy without causing deleterious side effects.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!